Functioning as a clinical-stage biotechnology company, Recursion Pharmaceuticals, Inc. (NASDAQ:RxRX) organizes around decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994 (in Phase 2 clinical trial) to treat cerebral cavernous malformation; REC-2282 ( in Phase 2/3 clinical trial) for treatment of neurofibromatosis type 2; REC-4881, (in Phase 2 clinical trial) to treat familial adenomatous polyposis; REC-3964 (Phase 1 clinical trial) to treat Clostridioides difficile infection; and REC-4881 ( in Phase 1b/2 clinical trial) to treat AXIN1 or APC mutant cancers. The firm's preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. Fairly active in SBIR until shortly befor going puiblic, with over 500 employees the firm now exceeds SBIR size standards. The company has collaboration and related agreements with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
